When facing amyotrophic lateral sclerosis, understanding the available treatment options becomes a crucial part of the journey. While there is currently no cure that stops or reverses this progressive disease, medical science has made significant strides in developing therapies that can help manage symptoms, slow the rate of decline, and potentially prolong survival. The approach to treating ALS is highly personalized, depending on how far the disease has progressed, which symptoms are present, and each person’s unique medical situation.

Hope Through Treatment: What Modern Medicine Offers for ALS

The main goals when treating amyotrophic lateral sclerosis focus on maintaining quality of life, preserving independence for as long as possible, managing uncomfortable symptoms, and supporting both patients and their families through the disease journey. Because ALS affects each person differently, treatment must be carefully tailored to address individual needs. Some people may experience symptoms that progress quickly, while others may have a slower disease course that spans many years.^[1][2]

Medical societies and health organizations have established treatment guidelines that doctors follow when caring for people with ALS. These recommendations are based on years of research and clinical experience. However, beyond these standard approaches, researchers around the world are actively investigating new therapies through clinical trials. These studies test innovative treatments that may offer additional benefits to patients in the future. Participating in such research can provide access to cutting-edge therapies while contributing to scientific knowledge that may help others.^[9]

Treatment for ALS requires a team approach. This typically includes neurologists who specialize in ALS, physical therapists who help maintain mobility and strength, occupational therapists who assist with daily activities, speech therapists who address communication and swallowing difficulties, respiratory therapists who manage breathing problems, nutritionists who ensure adequate nutrition, and mental health professionals who support emotional wellbeing. This multidisciplinary care approach has been shown to improve quality of life and may even extend survival compared to treatment by a single physician alone.^[11]

Standard Treatment Approaches: The Foundation of ALS Care

The first medication approved specifically for ALS was riluzole, which became available in December 1995. This oral medication works by reducing levels of glutamate, a molecule that plays a role in signaling between nerve cells and motor neurons. When glutamate levels become too high, it can damage motor neurons. By moderating glutamate activity, riluzole may slow the progression of motor neuron damage. Clinical trials showed that riluzole could prolong survival in people with ALS by approximately three to six months. While this may seem modest, for many patients and families, these additional months are precious. The medication is generally safe but can cause side effects including fatigue, nausea, and potential liver damage. Doctors typically recommend that people taking riluzole limit alcohol intake and undergo regular blood tests to monitor liver function.^[11]

Another important medication approved by the U.S. Food and Drug Administration is edaravone. This drug has been shown to reduce the rate of functional decline in some people with ALS. The way it works differs from riluzole, as edaravone acts as an antioxidant that may protect nerve cells from oxidative stress damage. Initially, edaravone was given as an intravenous infusion, requiring patients to visit a medical facility for treatment. However, an oral formulation has since become available, making the treatment more convenient. Not all patients qualify for edaravone treatment, as studies have shown it works best in people who meet certain criteria related to disease stage and progression rate.^[9]

A combination medication called sodium phenylbutyrate/ursodoxicoltaurine has also received FDA approval for ALS treatment. This therapy addresses cellular stress pathways that may contribute to motor neuron death. By targeting multiple mechanisms within cells, this combination approach offers another option for patients seeking to slow disease progression.^[9]

For people with ALS caused by mutations in the SOD1 gene, a specific medication called tofersen has been approved. This represents an important advance because it targets the underlying genetic cause of disease in this specific patient population. Tofersen works by reducing production of the abnormal SOD1 protein that contributes to motor neuron damage. Genetic testing can determine whether a person carries SOD1 mutations and might benefit from this targeted therapy. This personalized medicine approach demonstrates how treatment is becoming increasingly tailored to individual genetic profiles.^[9]

Beyond disease-slowing medications, many other treatments help manage the diverse symptoms that ALS causes. Dextromethorphan/quinidine is approved to treat pseudobulbar affect, a condition that causes uncontrollable episodes of laughing or crying that don’t match a person’s actual emotions. This symptom can be distressing and socially isolating, so effective treatment significantly improves quality of life.^[9]

Muscle stiffness and spasms, known as spasticity, affect many people with ALS. Several medications can help relax muscles and reduce cramping, including baclofen, tizanidine, and others. Physical therapy exercises and gentle stretching also play important roles in managing muscle tightness. When swallowing becomes difficult, a condition called dysphagia, speech therapists can teach safe swallowing techniques and recommend dietary modifications. Many patients eventually need a feeding tube, typically placed through the abdominal wall directly into the stomach in a procedure called a PEG (percutaneous endoscopic gastrostomy). This ensures adequate nutrition and hydration even when oral eating becomes unsafe due to choking risk.^[2]

Pain management is also important, although ALS typically does not cause severe pain in early stages. When pain does occur, it usually results from muscle cramps, joint stiffness from reduced mobility, or pressure from prolonged sitting or lying in one position. Treatment may include medications, physical therapy, massage, heat or cold therapy, and proper positioning with supportive cushions and mattresses. Mental health support addresses the anxiety and depression that commonly affect both patients and caregivers. Counseling, support groups, and sometimes medications can help people cope with the emotional challenges of living with ALS.^[1][2]

The duration of treatment varies because ALS affects each person differently. Some treatments, like riluzole, are typically continued for as long as they are tolerated and the person can swallow pills or receive them through a feeding tube. Regular follow-up appointments, usually every three months at specialized ALS clinics, allow the medical team to monitor disease progression, adjust treatments, and address new symptoms as they arise. These clinic visits often involve assessments using standardized tools like the ALSFRS-R (ALS Functional Rating Scale-Revised), which tracks changes in physical function over time.^[11]

Treatment in Clinical Trials: The Frontier of ALS Research

While approved treatments provide important benefits, researchers continue searching for more effective therapies through clinical trials. These studies test new drugs, devices, and treatment approaches that may eventually become standard care. Clinical trials are carefully designed to ensure participant safety while gathering scientific evidence about whether new treatments work.^[12]

Clinical trials proceed through several phases, each with specific goals. Phase I trials primarily test safety, usually involving small numbers of participants. Researchers want to understand what doses can be given safely and what side effects might occur. Phase II trials expand to larger groups and begin evaluating whether the treatment shows signs of effectiveness. These studies measure how the treatment affects disease markers or symptoms. Phase III trials involve even larger patient populations and compare the new treatment directly against standard care or placebo to determine whether it provides meaningful benefits. Only after successful completion of these phases does a treatment typically receive regulatory approval.^[12]

Many different types of innovative therapies are currently being investigated in ALS clinical trials around the world. Some promising approaches include gene therapy, which aims to correct or compensate for genetic defects that contribute to ALS. While most effective for familial ALS with known genetic causes, some gene therapy strategies may also benefit sporadic ALS cases. These treatments often use modified viruses to deliver corrected genes or to reduce production of harmful proteins.^[12]

Stem cell therapy represents another exciting area of investigation. Researchers are exploring whether stem cells can be used to replace damaged motor neurons, provide supportive factors that protect remaining neurons, or modify the disease process in other ways. Some studies have shown that stem cell treatments appear safe and may provide modest benefits, though more research is needed to understand their full potential and optimal use.^[12]

Immunotherapy approaches aim to modify the immune system’s role in ALS. While ALS is not primarily an autoimmune disease, research suggests that immune system dysfunction contributes to disease progression. Some trials test medications that calm excessive immune responses, while others try to harness immune cells to protect motor neurons. These treatments must carefully balance reducing harmful inflammation while preserving the immune system’s beneficial functions.^[12]

Scientists are also investigating various enzyme inhibitors and other drugs that target specific molecular pathways involved in ALS. These include medications that address oxidative stress, inflammation, protein misfolding, mitochondrial dysfunction, and other cellular problems that occur in ALS. By understanding the complex biological mechanisms that lead to motor neuron death, researchers can design treatments that intervene at specific points in the disease process.^[12]

Some clinical trials focus on neuroprotective agents that aim to shield motor neurons from damage. These treatments might work by improving energy production in nerve cells, reducing toxic protein accumulation, enhancing cellular cleanup mechanisms, or supporting the cells that surround and nourish motor neurons. While individual treatments have had mixed results, researchers continue refining their approaches based on growing scientific understanding.^[12]

Another important area involves antisense oligonucleotides, which are molecules designed to reduce production of specific disease-causing proteins. Tofersen, the approved treatment for SOD1-related ALS, belongs to this class. Researchers are developing similar treatments for other genetic forms of ALS, targeting different mutated genes. This personalized medicine approach may eventually provide specific treatments for many genetic variants of ALS.^[9]

Preliminary results from various clinical trials have shown mixed outcomes. Some treatments demonstrated improvements in certain clinical parameters, such as slowing the rate of functional decline or stabilizing muscle strength for periods of time. Others showed favorable safety profiles, meaning participants tolerated them well with manageable side effects, even if clear effectiveness wasn’t yet proven. A few trials have been discontinued when treatments showed no benefit or raised safety concerns, which is an important part of the research process that protects patients and helps focus resources on more promising approaches.^[12]

The search for effective ALS treatments is complicated by the disease’s complexity. ALS likely has multiple causes, and what works for one person may not help another. This is why researchers increasingly focus on understanding different ALS subtypes and developing targeted treatments. Biomarkers that can predict treatment response and track disease activity more precisely are also being developed. These tools will help match patients with treatments most likely to benefit them.^[12]

Beyond drugs, researchers are investigating technological solutions such as brain-computer interfaces that might help people with advanced ALS communicate or control assistive devices using brain signals. While these technologies are still experimental, they represent innovative approaches to maintaining quality of life even as physical abilities decline. Clinical trials also test various combinations of approved and experimental drugs, based on the theory that addressing multiple disease mechanisms simultaneously might prove more effective than single treatments.^[12]

Most Common Treatment Methods

• Disease-modifying medications
  • Riluzole (oral medication that reduces glutamate levels and may prolong survival by three to six months)
  • Edaravone (antioxidant available as intravenous or oral formulation that may slow functional decline)
  • Sodium phenylbutyrate/ursodoxicoltaurine (combination therapy targeting cellular stress pathways)
  • Tofersen (antisense oligonucleotide for SOD1 gene-related ALS that reduces abnormal protein production)
• Symptom management medications
  • Dextromethorphan/quinidine (for pseudobulbar affect causing uncontrollable laughing or crying)
  • Muscle relaxants like baclofen and tizanidine (for spasticity and muscle cramps)
  • Pain medications (for cramps, joint stiffness, and positioning-related discomfort)
  • Medications for excessive saliva production and drooling
• Respiratory support
  • Non-invasive ventilation using BiPAP machines (helps breathing through a mask, particularly during sleep)
  • Invasive ventilation via tracheostomy (surgical opening for full breathing support with mechanical ventilation)
  • Respiratory therapy and assisted cough techniques
• Nutritional support
  • Dietary modifications and safe swallowing techniques taught by speech therapists
  • PEG feeding tube placement (percutaneous endoscopic gastrostomy for direct stomach nutrition)
  • Nutritional counseling to maintain healthy weight and adequate caloric intake
• Physical and occupational therapy
  • Range of motion exercises to prevent joint stiffness
  • Stretching programs to reduce muscle tightness and spasticity
  • Mobility aids including walkers, wheelchairs, and lifts
  • Adaptive equipment for daily activities like dressing, eating, and bathing
• Communication support
  • Speech therapy for dysarthria (difficulty forming words)
  • Voice banking to preserve recorded speech before significant decline
  • Augmentative and alternative communication devices
  • Computer access adaptations including eye-tracking technology
• Mental health and psychosocial support
  • Counseling for patients and families dealing with anxiety and depression
  • Support groups connecting people with similar experiences
  • Medications for mood and emotional symptoms when needed
  • Advance care planning assistance for end-of-life decisions
• Multidisciplinary clinic care
  • Coordinated team approach including neurologists, therapists, nutritionists, respiratory specialists, and social workers
  • Regular monitoring with ALSFRS-R functional rating scale assessments
  • Proactive management of symptoms before they become severe